Lytgobi
What Lytgobi is used for
Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Lytgobi
- Active substance
- futibatinib
- Disease area
- Cholangiocarcinoma
- Medicine group
- antineoplastic agents
- ATC code
- L01EN04
- Marketing authorisation holder
- Taiho Pharma Netherlands B.V.
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Lytgobi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lytgobi used for?
Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
What is the active substance in Lytgobi?
Lytgobi contains futibatinib.
Who makes Lytgobi?
The EU marketing authorisation holder is Taiho Pharma Netherlands B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU